ArticleTranslational gastroenterology and hepatology2026
Dynamic feedback between IL-6 and TWIST1 drives pancreatic cancer progression.
Article in Translational gastroenterology and hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Interleukin-6 (IL-6) and twist family bHLH transcription factor 1 (TWIST1) are critical regulators of cancer progression, including in pancreatic ductal adenocarcinoma (PDAC), but how they dynamically interact remains unclear. Therefore, this study aimed to elucidate the interaction between IL-6 and TWIST1 and explore the underlying mechanisms involved in PDAC progression. Methods: The expression levels of IL-6, IL-6R, and TWIST1 were examined in 66 PDAC patient specimens, and their correlations with clinicopathological parameters and overall survival were analyzed. Integrative bioinformatics and experimental validation identified miR-543 as a key upstream regulator of TWIST1. The IL-6/miR-543/TWIST1 feedback circuit was subsequently verified in PDAC cell lines using quantitative PCR, western blotting, and luciferase reporter assays. Chromatin immunoprecipitation and luciferase reporter assays further confirmed the binding of TWIST1 to the IL-6 promoter. Results: Elevated expression of IL-6, IL-6R, and TWIST1 was detected in PDAC tissues and was significantly associated with poor patient prognosis. Bioinformatic and experimental analyses identified miR-543 as a pivotal mediator linking IL-6 signaling to TWIST1 regulation. Conclusions: The IL-6/miR-543/TWIST1 axis supports a dynamic feedback circuit that is associated with PDAC malignancy. Therapeutic targeting of this loop may provide an effective strategy to impede disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.